Reuters logo
BRIEF-Argentum Pharmaceuticals succeeds in starting patent cancellation trial against Novartis' AFINITOR
September 29, 2017 / 5:50 PM / 21 days ago

BRIEF-Argentum Pharmaceuticals succeeds in starting patent cancellation trial against Novartis' AFINITOR

Sept 29 (Reuters) - Argentum Pharmaceuticals:

* Argentum Pharmaceuticals says succeeds in starting patent cancellation trial against Novartis’ AFINITOR

* Says U.S. Patent & Trademark Office granted co’s petition for review against claims of last-expiring patent listed as covering Novartis’ AFINITOR Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below